Today

Agents

Chat

Arena

Discover

More

App

Myriad Genetics, Inc. <MYGN.O>: UBS Cuts Target Price to $3.6 From $6 - MYGN News | Rallies

Myriad Genetics, Inc. <MYGN.O>: UBS Cuts Target Price to $3.6 From $6

MYGN•2026-09-09

Related News

BioMarin submits FDA sNDA to expand Voxzogo use to children with hypochondroplasia

BMRN•2026-09-09

Nasdaq trade halt continues <MGN.O> volatility trading pause at 09:49 AM

MGN•2026-09-09

Nasdaq Trade Halt Continues UCFIW Reason Not Available at 09:40 AM

UCFIW•2026-09-09

Omada cites independent model projecting $11,142 gross medical cost savings per member over five years for GLP-1 program

OMDA•2026-09-09

Press Digest-Canada - September 9

BMO•2026-09-09